Search
necitumumab (Portrazza)
Indications:
- treatment of metastatic squamous cell lung cancer in treatment niave patients
Dosage:
Injection: 16 mg/mL (50 mL)
Adverse effects:
- most common
- skin rash
- hypomagnesemia* (can be fatal)
* boxed warning
- cardiac arrest, sudden death, hypomagnesemia
Mechanism of action:
- monoclonal antibody that blocks activity of EGFR
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
antineoplastic monoclonal antibody
EGF receptor (EGFR) inhibitor
References
- FDA News Release. November 24, 2015
FDA approves Portrazza to treat advanced squamous non-small
cell lung cancer
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474131.htm